

Texas Vendor Drug Program

Drug Use Criteria: Anti-diabetic Agents (Oral)

Publication History

1. Developed April 1994.
2. Revised **September 2020**; September 2018; September 2016; August 2014; July 2014; October 2012; January 2011; February 2008; November 2007; June 2003; July 2002; September 2001; June 2001; June 2000; July 1999; June 1998; June 1997; June 1996; September 1995.

Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document.

Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage.

Prepared by:

- Drug Information Service, UT Health San Antonio.
- The College of Pharmacy, The University of Texas at Austin.



TEXAS
Health and Human
Services

Medical and
Social Services

1 Dosage [*]

Oral antidiabetic agents are FDA-approved for use in type 2 diabetics as monotherapy or in combination with other oral antidiabetic agents or insulin, when the single agent alone, in addition to diet and exercise, does not provide sufficient glycemic control.

Oral sulfonylureas reduce blood glucose by stimulating insulin from pancreatic beta-cells as well as increasing responsiveness in insulin-sensitive tissues.

Although structurally dissimilar from oral sulfonylureas, meglitinides **such as nateglinide** also stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in pancreatic beta-cells.

Metformin is an oral hypoglycemic agent that improves glycemic control by decreasing hepatic glucose production and intestinal glucose absorption as well as improving insulin sensitivity through increased peripheral glucose uptake and utilization.

Alpha glucosidase inhibitors **such as acarbose** inhibit the ability of alpha glucosidase to convert nonabsorbable dietary starch and sucrose into absorbable glucose, which results in slower glucose absorption and reduced postprandial glucose levels.

The bile acid sequestrant, colesevelam, is FDA-approved for use to manage primary hyperlipidemia as well as type 2 diabetes as an adjunct to diet and exercise. The mechanism by which colesevelam lowers hemoglobin A1c (HbA1c) and improves glycemic control is unknown.

Bromocriptine, a dopamine agonist, is FDA-approved as Cycloset® to manage glycemic control in type 2 diabetes as an adjunct to diet and exercise through a currently undetermined mechanism.

The incretin hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic peptide (GIP), have been identified as important factors in glucose homeostasis. Released from the gut postprandially, GLP-1 and GIP stimulate insulin secretion from pancreatic beta cells in response to normal or elevated blood glucose

concentrations. GLP-1 also lowers glucagon excretion from pancreatic beta cells, which results in reduced hepatic glucose production, reduced appetite, slowed gastric emptying, and improved β -cell function. **Although GLP-1 agonists are primarily administered as a subcutaneous injection, semaglutide (Rybelsus®) recently received FDA approval as the first oral GLP-1 agonist used for the management of type 2 diabetes. Of note, semaglutide has not demonstrated a reduction in adverse cardiovascular outcomes while several injectable formulations have.**

DPP-IV inhibitors **such as sitagliptin** reduce inactivation of incretin hormones and improve glycemic control in type 2 diabetic patients without significant weight gain.

Thiazolidinediones **such as pioglitazone** are potent agonists of peroxisome proliferator-activated receptor-gamma (PPAR-gamma), receptors important for insulin action which are in adipose tissue, the liver, and skeletal muscle. Activation of these receptors affects the transcription of genes responsible for control of glucose and lipid metabolism. These agents, in the presence of insulin, decrease insulin resistance in the liver and at peripheral sites and improve insulin-dependent glucose disposal and reduce hepatic glucose output.

The thiazolidinediones, rosiglitazone and pioglitazone, have been associated with an increased risk of congestive heart failure most likely due to a greater incidence of fluid retention/edema associated with this drug class. Patients should be closely monitored for signs and symptoms of CHF, and thiazolidinedione dosages reduced or discontinued should symptoms develop. Thiazolidinediones are contraindicated for use in NYHA Class III or IV heart failure and are not recommended in patients with symptomatic heart failure.

Female patients treated with thiazolidinediones may be at increased risk for developing fractures. These agents have been shown to stimulate formation of more adipocytes rather than osteoblasts in bone. Thiazolidinediones may also decrease hip and femoral neck bone mineral density in older diabetic patients. Fractures currently reported with thiazolidinedione use have been limited to the humerus, hand and foot in female patients only. Further assessment of thiazolidinedione adverse skeletal effects is necessary to determine the risk-benefit ratio of these agents in diabetic patients. Female patients at higher fracture risk should be considered for bone mineral density assessment and bone strengthening therapies (e.g., calcium, vitamin D, bisphosphonates) prior to therapy initiation with thiazolidinediones.

A new class of medications, sodium-glucose co-transporter 2 (SGLT2) inhibitors, have been developed as additional tools to manage type 2 diabetes. **Examples include canagliflozin and empagliflozin.** These agents work by inhibiting SGLT2 transporters, which are in the proximal renal tubule, and reduce reabsorption of filtered glucose which causes increased glucose excretion and lower serum glucose concentrations.

1.1 Adults

Maximum recommended daily doses for available oral antidiabetic agents, both as monotherapy and as combination therapy, are summarized in Tables 1 and 2. Prescribed dosages exceeding these recommendations will be reviewed.

Table 1. Oral Antidiabetic Agents- Monotherapy: Alpha-Glucosidase Inhibitors (AGIs) Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
acarbose (Precose®, generics)	25 mg, 50 mg, 100 mg tablets	patients ≤ 60 kg: 150 mg/day, in three divided doses patients > 60 kg: 300 mg/day, in three divided doses
miglitol (Glyset®)	25 mg, 50 mg, 100 mg tablets	300 mg/day, in three divided doses

Table 2. Oral Antidiabetic Agents- Monotherapy: Biguanides Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
metformin (Glucophage®, generics)	500 mg, 850 mg, 1000 mg immediate-release tablets	2550 mg/day
metformin (Glucophage XR®, Fortamet®, Glumetza®, various generics)	500 mg, 750 mg, 1000 mg extended-release tablets	2000 mg/day (2500 mg/day Fortamet®)
metformin (Riomet®, generics)	oral solution 500 mg/5ml	2550 mg/day

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
metformin (Riomet® ER)	500 mg/ 5 mL extended release suspension	2000 mg/ day

Table 3. Oral Antidiabetic Agents- Monotherapy: Bile Acid Sequestrants Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
colesevelam (Welchol®, generic))	625 mg tablets	3.75 g/day, in single or two divided doses
colesevelam	3.75 g powder packet for oral suspension [#]	3.75 g/day as single dose

[#]dissolve in 4-8 ounces of water, fruit juice or diet soda and administer with a meal

Table 4. Oral Antidiabetic Agents- Monotherapy: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
alogliptin (Nesina®, generics)	6.25 mg, 12.5 mg, 25 mg tablets	25 mg/day
linagliptin (Tradjenta®)	5 mg	5 mg/day
saxagliptin (Onglyza®)	2.5 mg, 5 mg tablets	5 mg/day
sitagliptin (Januvia®)	25 mg, 50 mg, 100 mg tablets	100 mg/day

**Table 5. Oral Antidiabetic Agents- Monotherapy: Dopamine Agonists
Maximum Recommended Adult Daily Dosages**

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
bromocriptine (Cycloset®)	0.8 mg tablets	4.8 mg/day

Table 6. Oral Antidiabetic Agents- Monotherapy: Meglitinides Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
nateglinide (Starlix®, generics)	60 mg, 120 mg tablets	360 mg/day, in three divided doses
repaglinide (Prandin®, generics)	0.5 mg, 1 mg, 2 mg tablets	16 mg/day (in divided doses before meals, up to 4 times daily depending on meal number)

Table 7. Oral Antidiabetic Agents- Monotherapy: Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
canagliflozin (Invokana®)	100 mg, 300 mg tablets	300 mg/day
dapagliflozin (Farxiga®)	5 mg, 10 mg tablets	10 mg/day
empagliflozin (Jardiance®)	10 mg, 25 mg tablets	25 mg/day
ertugliflozin (Steglatro®)	5 mg, 15 mg tablets	15 mg/day

Table 8. Oral Antidiabetic Agents- Monotherapy: Sulfonylureas Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
chlorpropamide (various generics)	100 mg, 250 mg tablets	750 mg/day
glimepiride (Amaryl®, generics)	1 mg, 2 mg, 4 mg tablets	8 mg/day
glipizide (Glucotrol®, generics)	5 mg, 10 mg immediate-release tablets	40 mg/day
glipizide (Glucotrol XL®, generics)	2.5 mg, 5 mg, 10 mg extended-release tablets	20 mg/day
glyburide (generics)	1.25 mg, 2.5 mg, 5 mg nonmicronized tablets	20 mg/day
glyburide (Glynase®, generics)	1.5 mg, 3 mg, 6 mg micronized tablets	12 mg/day
tolazamide (various generics)	250 mg, 500 mg tablets	1000 mg/day
tolbutamide (generics)	500 mg tablet	3000 mg/day

Table 9. Oral Antidiabetic Agents- Monotherapy: Thiazolidinediones (TZDs) Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
pioglitazone (Actos®, generics)	15 mg, 30 mg, 45 mg tablets	45 mg/day
rosiglitazone (Avandia®)	2 mg, 4 mg tablets	8 mg/day in single or two divided doses

Table 10. Oral Antidiabetic Agents- Monotherapy: Glucagon-Like Peptide-1 (GLP-1) Agonist Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
semaglutide (Rybelsus®)	3 mg, 7 mg, 14 mg tablets	14 mg/ day

Table 11. Oral Antidiabetic Agents- Combination Therapy: Maximum Recommended Adult Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
alogliptin/ metformin (Kazano®, generics)	12.5 mg/500 mg, 12.5 mg/1000 mg tablets	25 mg/2000 mg/day
alogliptin/ pioglitazone (Oseni®, generics)	12.5 mg/15 mg, 12.5 mg/30 mg, 12.5 mg/45 mg, 25 mg/15 mg, 25 mg/30 mg, 25 mg/45 mg tablets	25 mg/45 mg/day
canagliflozin/ metformin (Invokamet®)	50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, 150 mg/1000 mg tablets	300 mg/2000 mg/day in two divided doses
canagliflozin/ metformin (Invokamet® XR)	50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, 150 mg/1000 mg extended-release tablets	300 mg/2000 mg/day once daily
dapagliflozin/ metformin (Xigduo® XR)	2.5 mg/1000 mg, 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg tablets	10 mg/2000 mg/day once daily
dapagliflozin/saxagliptin (Qtern®)	5 mg/ 5 mg , 10 mg/5 mg tablets	10 mg/5 mg/day once daily
dapagliflozin/ saxagliptin/ metformin (Qternmet® XR)	2.5 mg/ 2.5 mg/ 1000 mg, 5 mg/ 2.5 mg/ 1000 mg, 5 mg/ 5 mg/ 1000 mg, 10 mg/ 5 mg/ 1000 mg extended-release tablets	10 mg/ 5 mg/ 2000 mg daily
empagliflozin/ linagliptin (Glyxambi®)	10 mg/5 mg, 25 mg/5 mg tablets	25 mg/5 mg/day
empagliflozin/ metformin (Synjardy®)	5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/1000 mg tablets	25 mg/2000 mg/day in two divided doses
empagliflozin/ metformin (Synjardy® XR)	5 mg/ 1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, 25 mg/1000 mg extended-release tablets	25 mg/2000 mg/day once daily
empagliflozin/ linagliptin/ metformin (Trijardy® XR)	5 mg/ 2.5 mg/ 1000 mg, 10 mg/ 5 mg/ 1000 mg, 12.5 mg/ 2.5 mg/ 1000mg, 25 mg/ 5 mg/ 1000 mg extended-release tablets	25 mg/ 5 mg/ 2000 mg daily

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
ertugliflozin/ metformin (Segluromet®)	2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets	15 mg/2000 mg/day in two divided doses
ertugliflozin/ sitagliptin (Steglujan®)	5 mg/100 mg, 15 mg/100 mg tablets	15 mg/100 mg/day once daily
glipizide/ metformin (Metaglip®, generics)	2.5 mg/250 mg, 2.5 mg/500 mg (generic only), 5 mg/500 mg (generic only) tablets	<i>Patients with inadequate glycemic control on diet/exercise alone:</i> 10 mg/2000 mg/day <i>Patients with inadequate glycemic control on sulfonylurea and/or metformin:</i> 20 mg/2000 mg/day
glyburide/ metformin (Glucovance®, generics)	1.25 mg/250 mg, 2.5 mg/500 mg (generic only), 5 mg/500 mg (generic only) tablets	<i>Patients with inadequate glycemic control on diet/exercise alone:</i> 10 mg/2000 mg/day <i>Patients with inadequate glycemic control on sulfonylurea and/or metformin:</i> 20 mg/2000 mg/day
linagliptin/ metformin (Jentadueto®)	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg immediate-release tablets	5 mg/2000 mg/day in two divided doses
linagliptin/ metformin (Jentadueto® XR)	2.5 mg/1000 mg, 5 mg/1000 mg extended-release tablets	5 mg/2000 mg/day once daily
pioglitazone/ glimepiride (Duetact®, generics)	30 mg/2 mg, 30 mg/4 mg tablets	30 mg/4 mg once daily
pioglitazone/ metformin (ActoPlus Met®, generics)	15 mg/500 mg, 15 mg/850 mg immediate-release tablets	45 mg/2550 mg/day
pioglitazone/ metformin (ActoPlus Met XR®)	15 mg/1000 mg, 30 mg/1000 mg extended-release tablets	45 mg/2000 mg/day

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
repaglinide/ metformin (generics)	1 mg /500 mg, 2 mg/500 mg tablets	10 mg/2500 mg/day (no more than 4 mg/1000 mg/meal)
rosiglitazone/ metformin (Avandamet®)	2 mg/ 500 mg, 2 mg/ 1000 mg tablets	8 mg/ 2000 mg/ day
sitagliptin/ metformin (Janumet®)	50 mg/500 mg, 50 mg/1000 mg immediate-release tablets	100 mg/2000 mg/day in two divided doses
sitagliptin/ metformin (Janumet XR®)	50 mg/500 mg, 50 mg/1000 mg, 100 mg/1000 mg extended-release tablets	100 mg/2000 mg/day once daily

1.2 Pediatrics

Oral sulfonylureas, alpha-glucosidase inhibitors, pioglitazone, meglitinides, DPP-4 inhibitors, and SGLT2 inhibitors are not FDA-approved for use in pediatric patients as safety and efficacy have not been determined in this patient population. Sufficient data are not available to assess rosiglitazone safety and efficacy in pediatric patients.

Metformin immediate-release and **Riomet® ER (metformin extended-release oral suspension)** are FDA-approved for use in pediatric type 2 diabetic patients 10 years of age and older as an adjunct to diet in exercise to aid in controlling blood glucose. Maximum recommended oral antidiabetic doses in pediatric patients are summarized in Table 3. Dosages exceeding these recommendations will be reviewed.

Table 12. Recommended Pediatric Oral Antidiabetic Agents- Monotherapy: Maximum Recommended Daily Dosages

Drug Name	Dosage Form/ Strength	Maximum Recommended Dosage
metformin	immediate-release tablets	≥ 10 years of age: 2000 mg/day, in divided doses
metformin (Riomet® ER)	extended-release suspension	≥ 10 years of age: 2000 mg once daily

1.3 Renal Impairment

Acarbose should be avoided in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/minute/ 1.73m^2 . Miglitol should be avoided in patients with an eGFR < 25 mL/minute/ 1.73m^2 .

Metformin should be used cautiously in patients with an eGFR below 60 mL/ minute/ 1.73m^2 . Renal function should be closely monitored in patients with an eGFR of 30 - 59 mL/ minute/ 1.73m^2 , with doses decreased by 50% in patients with an eGFR of 30 - 59 mL/ minute/ 1.73m^2 . Metformin doses should be discontinued in patients with an eGFR < 30 mL/ minute/ 1.73m^2 .

In moderate renal impairment (CrCl 30 to < 60 ml/min), alogliptin dosages should be reduced to 12.5 mg daily, while in patients with severe renal impairment (CrCl 15 to < 30 ml/min), alogliptin dosages should not exceed 6.25 mg daily.

Linagliptin dosages do not need to be adjusted for renal insufficiency. Patients on linagliptin combination therapy with a CrCl < 30 ml/min may have increased risk of hypoglycemia and may need more frequent monitoring and/or dose adjustments.

Saxagliptin dosages should be reduced to 2.5 mg once daily in patients with CrCl < 50 ml/min or in patients prescribed a strong CYP3A4 inhibitor (e.g., ketoconazole).

Sitagliptin dosages should be adjusted in adult patients with renal insufficiency. Patients with moderate renal insufficiency (CrCl > 30 to < 50 ml/min corresponding to serum creatinine levels between 1.7 and 3 mg/dl in men and 1.5 and 2.5 mg/dl in women) should receive sitagliptin 50 mg daily, while patients with severe renal insufficiency (CrCl < 30 ml/min corresponding to serum creatinine levels in men > 3 mg/dl or > 2.5 mg/dl in women) or those patients with end stage renal disease requiring hemodialysis or peritoneal dialysis should receive sitagliptin 25 mg daily.

Canagliflozin doses in patients with renal impairment should be reduced to 100 mg daily when the estimated glomerular filtration rate (eGFR) is 30 - 59 ml/min/ 1.73 m^2 and avoided when eGFR is < 30 ml/min/ 1.73 m^2 . **Patients may continue up to 100mg daily of canagliflozin when eGFR is < 30 ml/min/ 1.73 m^2 if they have albuminuria > 300 mg/day.**

Dapagliflozin therapy is not recommended for use in patients with eGFR < 45 ml/min/ 1.73 m^2 .

Empagliflozin therapy should not be initiated in patients with eGFR < 45 ml/min/1.73m² and should be discontinued in those patients who develop impaired renal function (GFR < 45 ml/min/1.73 m²).

Ertugliflozin therapy should not be initiated in patients with an eGFR between 30-60 mL/min/1.73m², and therapy should be discontinued if eGFR is persistently between 30-60 mL/min/1.73m². Use is contraindicated in eGFR < 30 mL/min/1.73m².

Chlorpropamide dosing should be reduced by 50% in patients with mild renal failure, and it should be avoided in patients with moderate to severe renal failure (eGFR < 50 mL/min/1.73m². Glyburide should be avoided in patients with renal impairment. If use is necessary, start at 1.25 mg daily. All sulfonylurea medications should be initiated with caution and at a reduced starting dose to minimize the risk of hypoglycemic events.

2 Duration of Therapy

There is no basis for limiting the duration of oral antidiabetic therapy as diabetes is a chronic disorder.

3 Duplicative Therapy [*]

Administering two or more oral sulfonylureas concurrently is not justified. The concomitant use of two or more oral sulfonylureas will be reviewed.

Combined administration of nateglinide or repaglinide and oral sulfonylureas is not justified as both drug classes stimulate insulin secretion. Adjunctive use of meglitinides and oral sulfonylureas will be reviewed.

The risk of hypoglycemia may increase when acarbose or miglitol is added to pre-existing oral hypoglycemic or insulin therapy. Blood glucose levels should be monitored closely when alpha glucosidase inhibitor therapy is initiated in patients already receiving oral hypoglycemic or insulin therapy.

Adjunctive administration of rosiglitazone and insulin is not recommended as a greater incidence of myocardial ischemic events was observed in clinical trials when rosiglitazone was added to insulin therapy.

Concurrent administration of thiazolidinediones or metformin with sulfonylureas may result in an increased frequency of hypoglycemic episodes. Blood glucose levels should be closely monitored if patients are prescribed thiazolidinediones or metformin and oral sulfonylureas concomitantly, and oral sulfonylurea dosage reductions should be considered.

Concurrent administration DDP-4 inhibitors and sulfonylureas, with or without metformin, have resulted in significant reductions in HbA1c and fasting plasma glucose compared to placebo. The risk of hypoglycemia with DDP-4 inhibitors in combination with metformin and TZDs is comparable to that observed with placebo; however, the incidence of hypoglycemia in patients prescribed DDP-4 inhibitors concurrently with sulfonylureas is greater than that seen with placebo. The incidence of hypoglycemia in patients prescribed DDP-4 inhibitors and insulin concurrently has not been adequately evaluated. Therefore, blood glucose levels should be closely monitored if patients are prescribed DDP-4 inhibitors and oral sulfonylureas or insulin concomitantly, and oral sulfonylurea dosage reductions should be considered.

Concomitant use of multiple SGLT2 inhibitors is not recommended due to similar pharmacologic mechanisms and increased risk of adverse events. Combined administration is not advised and will be reviewed.

4 Drug-Drug Interactions [*]

Patient profiles will be reviewed to identify those drug regimens which may result in clinically significant drug-drug interactions. Drug-drug interactions considered clinically relevant for oral antidiabetic agents are summarized in **Table 13**. Only those drug-drug interactions classified as clinical significance level 1 or those considered life-threatening which have not yet been classified will be reviewed.

Table 13. Oral Antidiabetic Agent Drug-Drug Interactions

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
acarbose	digoxin	adjunctive administration may result in decreased digoxin levels; acarbose most likely impairs digoxin absorption	avoid concurrent administration; separate administration by 6 hours to avoid interaction; monitor digoxin levels	2-major (CP)
alpha-glucosidase inhibitors (AGIs)	digestive enzymes	combined therapy may result in decreased AGI absorption, reduced pharmacologic effects	avoid concurrent administration	moderate (DrugReax) 2-major (CP)
antidiabetic agents (ADAs)	ACE inhibitors/angiotensin receptor blockers (ARBs)	combined therapy may result in increased risk of hypoglycemia, most likely due to ACE inhibitor/ARB improved insulin sensitivity	monitor glycemic control when initiating or changing therapy	3-moderate (CP)
ADAs	atypical antipsychotics (AAs)	combined therapy may result in loss of glycemic control; AAs may increase insulin resistance or inhibit beta cells	monitor for loss of glycemic control; adjust doses as necessary	3-moderate (CP)
ADAs	beta blockers (BB)	BB may prolong hypoglycemia (interference with mobilization of glycogen stores), promote hyperglycemia (inhibit insulin secretion/decrease tissue insulin sensitivity), as well as mask signs/symptoms of hypoglycemia	administer cautiously together; consider cardioselective BB due to lesser effects on glucose metabolism, less masking of hypoglycemic signs/symptoms	moderate (DrugReax) 3-moderate (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
ADAs	fluoroquinolones	combined administration may increase risk of hyper- or hypoglycemia; mechanism unknown	closely monitor serum glucose levels; adjust ADA doses as needed	major (DrugReax) 3-moderate (CP)
ADAs	MAOIs	adjunctive therapy may result in additive glucose-lowering effects; MAOIs may stimulate insulin secretion	closely monitor serum glucose levels; decrease antidiabetic agent doses as necessary	moderate (DrugReax) 3-moderate (CP)
ADAs	somatostatin analogues (SAs) (e.g., octreotide, pasireotide)	concurrent use may impair glucose regulation as SAs inhibit insulin and glucagon secretion; substantially increased blood glucose levels may result	monitor closely for changes in blood glucose control before and throughout SA therapy; adjust antidiabetic doses as needed	major (DrugReax) 2-major (CP)
ADAs	thiazide diuretics	combined therapy may antagonize hypoglycemic effects of ADAs as thiazides increase blood glucose levels in dose-related manner	utilize lower thiazide doses, if possible; monitor serum glucose levels; adjust ADA doses as needed	3-moderate (CP)
bromocriptine	ergot alkaloids	combined therapy may increase risk of ergot toxicity (e.g., angina, paresthesias) as bromocriptine is ergot derivative	avoid using together	1-severe (CP)
bromocriptine	metoclopramide	combined therapy may attenuate bromocriptine pharmacological effects; metoclopramide is dopamine antagonist	avoid concurrent use	2-major (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
bromocriptine	select macrolides (e.g., clarithromycin, erythromycin)	potential for increased bromocriptine pharmacologic/ adverse effects due to decreased hepatic metabolism by macrolide	monitor patient for adverse effects; decrease bromocriptine dose as necessary	moderate (DrugReax) 3-moderate (CP)
bromocriptine	serotonin-receptor agonists (e.g., sumatriptan)	increased risk of serious coronary ischemia due to potential for additive vasospasm	avoid concurrent administration within 24 hours of each other	2-major (CP)
bromocriptine	drugs metabolized by CYP3A4 (e.g., tacrolimus, cyclosporine, sirolimus)	potential for decreased cyclosporine/ sirolimus/ tacrolimus clearance, enhanced pharmacologic/ adverse effects; bromocriptine is CYP3A4 inhibitor	monitor for increased pharmacologic/ adverse effects; consider reducing dose of CYP3A4 substrate	2-major (CP)
canagliflozin	UGT enzyme inducers (e.g., rifampin)	adjunctive administration may decrease canagliflozin AUC by 51% and reduce therapeutic efficacy as canagliflozin is metabolized through O-glucuronidation by several UGT enzymes (UGT1A9 and UGT2B4)	administer cautiously together; may increase canagliflozin dose to 300 mg daily during adjunctive therapy with UGT enzyme inducers or may consider alternative antidiabetic agents metabolized by different mechanisms	major (DrugReax) 2-major (CP)
colesevelam	cyclosporine	decreased cyclosporine peak serum concentrations and AUC with combined therapy	administer cyclosporine at least 4 hours prior to colesevelam; monitor serum cyclosporine levels	3-moderate (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
colesevelam	oral contraceptives (OC)	decreased peak ethinyl estradiol/norethindrone serum levels, AUC with combined therapy	administer OC at least 4 hours before colesevelam	3-moderate (CP)
colesevelam	thyroid hormones (TH) (e.g., levothyroxine, liothyronine)	combined therapy may cause reduced thyroid hormone absorption due to nonspecific binding to colesevelam	take TH at least 4 hours prior to colesevelam; monitor for adequate thyroid response; adjust TH dose as needed	moderate (DrugReax) 3-moderate (CP)
glimepiride	voriconazole	combined therapy may increase glimepiride levels and risk of hypoglycemia; voriconazole inhibits CYP2C9, glimepiride metabolized by CYP2C9	monitor for hypoglycemia; consider lowering glimepiride dose	major (DrugReax) 3-moderate (CP)
glyburide, TZDs	bosentan	increased risk of elevated liver enzymes when used concurrently; bosentan, a CYP2C9 and CYP3A4 inducer, may decrease glyburide and TZD levels/reduce hypoglycemic effects; glyburide, rosiglitazone metabolized by CYP2C9, pioglitazone metabolized by CYP3A4	combined therapy contraindicated; choose alternative ADA	glyburide -1-severe; TZDs -2-major (CP) glyburide -contraindicated (DrugReax)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
linagliptin	CYP3A4 and p-glycoprotein inducers	combined therapy may significantly decrease linagliptin concentrations decrease efficacy; linagliptin metabolized by CYP3A4	administer cautiously together; monitor serum glucose levels	rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, St. John's wort - major (DrugReax) others - moderate (DrugReax)
meglitinides, sulfonylureas, TZDs	rifamycins	combined therapy may result in reduced ADA serum levels and loss of hypoglycemic control due to enhanced ADA hepatic metabolism by rifamycin	closely monitor serum glucose levels; adjust ADA dose as necessary	moderate (DrugReax) 4-minor (CP)
metformin	dofetilide	increased risk of lactic acidosis; dofetilide decreases metformin elimination by competing for renal tubular transport system; potential for increased dofetilide serum concentrations and cardiotoxicity risk	manufacturer recommends avoiding concurrent use	1-severe (CP) major (DrugReax)
pioglitazone	tolvaptan	combined therapy may decrease tolvaptan concentrations; pioglitazone is CYP3A4 inducer, tolvaptan is metabolized by CYP3A4	avoid concurrent use if possible; if combined therapy necessary, increase tolvaptan dose and monitor efficacy	major (DrugReax)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
repaglinide, TZDs	gemfibrozil	combined therapy increases potential for elevated repaglinide or TZD levels/amplified repaglinide or TZD hypoglycemic effects due to gemfibrozil inhibition of CYP2C8; repaglinide, TZDs metabolized by CYP2C8	avoid concurrent administration; if combination cannot be avoided, use lower repaglinide dose	contraindicated (DrugReax) 1-severe (CP)
repaglinide	CYP3A4 inhibitors (e.g., rifamycins, macrolides, itraconazole)	combined therapy may significantly increase repaglinide concentrations and increase hypoglycemia risk; repaglinide metabolized by CYP3A4	administer cautiously together; monitor for hypoglycemia; adjust repaglinide dose as necessary	itraconazole-major ; others – moderate (DrugReax) 2-major (CP)
repaglinide	cyclosporine	cyclosporine is CYP3A4 inhibitor, also inhibits uptake of repaglinide into liver by inhibiting OATP1B1, which increases risk of elevated repaglinide levels and hypoglycemia when given concurrently	administer cautiously together; closely monitor glycemic control; adjust repaglinide dose as necessary	2-major (CP)
repaglinide	isophane insulin (NPH)	combined therapy caused myocardial ischemia in clinical trials	avoid concurrent administration	2-major (CP)
rosiglitazone	nitrate	in clinical trials, increased risk of myocardial ischemia in patients receiving combined therapy	avoid concurrent administration (manufacturer recommendations)	2-major (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
saxagliptin	CYP3A4/5 inhibitors (e.g., ketoconazole, erythromycin, fluconazole)	combined therapy may increase saxagliptin levels and risk of hypoglycemia; saxagliptin metabolized by CYP3A4/5	utilize lower saxagliptin dose (2.5 mg daily) with strong CYP3A4/5 inhibitors (e.g., ketoconazole); adjunctive therapy with moderate CYP3A4/5 inhibitors does not warrant dosage adjustments	2-major (CP)
sulfonylureas	methotrexate	concurrent administration may result in methotrexate displacement from protein binding sites and increased risk of methotrexate toxicity	consider avoiding combination; watch for signs of toxicity	2-major (CP)
sulfonylureas	sulfonamides	combined therapy may exaggerate sulfonylurea hypoglycemic effects; sulfonamides may inhibit sulfonylurea metabolism or displace sulfonylurea from protein binding site; glipizide, glyburide not significantly affected due to nonionic binding of these agents	use combination cautiously; closely monitor serum glucose levels, observe for signs/symptoms of hypoglycemia, reduce sulfonylurea dose as necessary	moderate (DrugReax) 3-moderate (CP)
tolbutamide	CYP2C9 inhibitors (e.g., imatinib, sorafenib, delavirdine)	combined therapy may increase tolbutamide serum concentrations, increase risk of hypoglycemia	closely monitor serum glucose levels	2-major (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level*
TZDs	insulins	combined therapy associated with increased risk of heart failure and/or edema and myocardial ischemic events	manufacturer recommends avoiding concurrent use	2-major (CP)

*CP = Clinical Pharmacology

5 References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; **2020**. Available at: <http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/>. **Accessed August 31, 2020**.
2. IMB Micromedex® DRUGDEX® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com.libproxy.uthscsa.edu>. **Accessed August 31, 2020**.
3. Facts & Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; **2020**. Available at: <http://online.factsandcomparisons.com.ezproxy.lib.utexas.edu/index.aspx>. **Accessed August 31, 2020**.
4. Linagliptin tablets (Tradjenta®) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., **April 2020**.
5. Linagliptin and metformin hydrochloride (Jentadueto®) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., **April 2020**.
6. Sitagliptin and metformin hydrochloride extended-release (Janumet XR®) package insert. Merck & Co., Inc., **August 2019**.
7. Metformin extended-release tablets (Glumetza®) package insert. **Santarus, Inc., August 2019**.
8. Metformin oral solution (Riomet®) package insert. **Sun Pharmaceutical Industries Inc., December 2018**.
9. **Metformin extended release oral solution (Riomet® ER) package insert. Sun Pharmaceutical Industries Inc., November 2019**.
10. Metformin extended-release tablets (Fortamet®) package insert. **Shionogi Inc., November 2018**.
11. Alogliptin tablets (Nesina®) package insert. Takeda Pharmaceuticals America, Inc., **June 2019**.
12. Dapagliflozin tablets (Farxiga®) package insert. **AstraZeneca, May 2020**.

13. Canagliflozin tablets (Invokana®) package insert. Janssen Pharmaceuticals, Inc., **August 2020.**
14. Colesevelam tablets, oral suspension (Welchol®) package insert. Daiichi Sankyo, Inc., **August 2020.**
15. Bromocriptine tablets (Cycloset®) package insert. **Santarus Inc., July 2020.**
16. Empagliflozin tablets (Jardiance®) package insert. Boehringer Ingelheim, **April 2020.**
17. Canagliflozin and metformin tablets (Invokamet®) package insert. Janssen Pharmaceuticals, Inc., **August 2020.**
18. **Rosiglitazone and metformin tablets (Avandamet®) package insert. GlaxoSmithKline , April 2017.**
19. Sitagliptin/metformin extended-release tablets (Janumet® XR) package insert. Merck & Co., Inc., **August 2019.**
20. Ertugliflozin tablets (Steglatro®) package insert. Merck & Co., Inc., **January 2020.**
21. **Semaglutide (Rybelsus®) tablets package insert. Novo Nordisk, January 2020.**
22. Dapagliflozin/saxagliptin tablets (Qtern®) package insert. AstraZeneca, **January 2020.**
23. **Dapagliflozin/ saxagliptin/ metformin (Qternmet® XR) package insert. AstraZeneca, January 2020.**
24. United States Food and Drug Administration. FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program. (11/4/11) Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm277629.htm>. **Accessed August 31, 2020.**
25. **United States Food and Drug Administration. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. (11/25/2013) Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-removal-some-prescribing-and-dispensing-restrictions>. Accessed August 31, 2020.**
26. **United States Food and Drug Administration. FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines. (12/16/2015) Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-eliminates-risk-evaluation-and-mitigation-strategy-rems>. Accessed August 31, 2020.**

27. Nathan DM. Diabetes: Advances in Diagnosis and Treatment. *JAMA*. 2015;14(10):1052-62.
28. Halas CJ. Nateglinide. *Am J Health Syst Pharm*. 2001;58:1200-5.
29. Plosker GL, Figgitt DP. Repaglinide: a pharmaco-economic review of its use in type 2 diabetes mellitus. *Pharmacoeconomics*. 2004;22:389-411.
30. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med*. 2007;147:386-99.
31. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. *Cochrane Database Syst Rev*. 2006;4:CD005061.
32. Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2007;2:CD004654.
33. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. *JAMA*. 2007;298:1189-95.
34. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA*. 2007;298:1180-8.
35. Home PD, Jones NP, Pocock SJ, et al., for the RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. *Diabet Med*. 2007;24:626-34.
36. Bloomgarden ZT. Thiazolidinediones. *Diabetes Care*. 2005;28:488-93.
37. Granberry MC, Hawkins JB, Franks AM. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. *Am J Health Syst Pharm*. 2007;64:931-6.
38. Kahn SE, Haffner SM, Heise MA, et al, and the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med*. 2006;355:2427-43.
39. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. *Lancet*. 2005; 366:1279-89.
40. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. *J Am Coll Cardiol*. 2007;49:1696-704.
41. Mascitelli L, Pezzetta F. Thiazolidinediones and the risk of nontraumatic fractures in patients with diabetes. *Arch Intern Med*. 2006;166:126.
42. Short R. Fracture risk a class effect of thiazolidinediones in women. *BMJ*. 2007;334:551.

43. Schwartz AV, Sellmeyer DE. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? *Diabetes Care*. 2007; 30: 1670-1.
44. Hermansen K, Kipnes M, Luo E, et al, for the Sitagliptin O35 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab*. 2007; 9: 733-45.
45. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab*. 2007; 9: 194-205.
46. Miller SA, St. Onge EL. Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *Ann Pharmacother*. 2006; 40: 1336-43.
47. Sitagliptin (Januvia) for type 2 diabetes. *Med Lett Drugs Ther*. 2007; 49: 1-3.
48. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care*. 2006; 29: 2638-43.
49. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care*. 2006; 29: 2632-7.
50. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*. 2006; 28: 1556-68.
51. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. *Diabetes Obes Metab*. 2008; 10: 376-386.
52. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. *Int J Clin Pract*. 2009; 63(9): 1395-1406.
53. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. *Diabetes Care*. 2009; 32(9): 1649-55.

54. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. *Diabetes Care*. 2010;33(7):1503-8.
55. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. *Diabetes Care*. 2000;23(8):1154-61.
56. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. *Arch Intern Med*. 2008;168(18):1975-83.
57. Brunetti L, Hermes-Desantis ER. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. *Ann Pharmacother*. 2010;44(7):1196-1206.
58. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ*. 2012; 344:e1369.
59. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. *Ann Intern Med*. 2013;159:262-274.
60. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. *Drug Saf*. 2005;28:601-31.
61. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med*. 2016;164:740-51.
62. **American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes -2020. *Diabetes Care*. 2020;43(Suppl. 1): S98–S110.**